Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Do you generally find plain radiographs useful as part of your baseline evaluation in suspected rheumatoid arthritis?
How do you help patients understand the difference between prolonged morning stiffness and pain?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
